All HHS Contracts — August 05, 2026

Icahn School of Medicine at Mount Sinai received a $186.2 million cost-no-fee contract from the CDC, with a potential value of $340.8 million over 8 years. The cost-no-fee structure provides stable revenue but zero profit, limiting financial upside for the institution.

The entire digest's contract value is concentrated in a single award to a non-profit educational institution (Icahn School of Medicine at Mount Sinai). This creates a lack of actionable signals for public equity investors, as the entity is not publicly traded.

The cost-no-fee pricing structure means the contractor bears no profit risk but also has no profit incentive. Performance issues or compliance problems could affect future awards, but the financial risk to the contractor is low.

The CDC's multi-year, $340.8M commitment to a Clinical Center of Excellence signals sustained federal investment in public health research and clinical care. This could create secondary opportunities for publicly traded healthcare service providers or clinical research organizations (CROs) that partner with or subcontract from institutions like Icahn.

This $186.2M CDC contract to a non-profit educational institution demonstrates stable, long-term civilian healthcare funding, but the cost-no-fee structure limits direct financial upside for public companies.

{"entity" => "Icahn School of Medicine at Mount Sinai", "reason" => "Recipient of the sole $186.2M contract in this digest; its performance and option exercises will determine future funding.", "trigger" => "Option exercise announcements or contract modifications from the CDC."}

{"entity" => "Healthcare Services Sector", "reason" => "Potential indirect beneficiary if Icahn School of Medicine subcontracts clinical services to publicly traded firms.", "trigger" => "Subcontract awards or partnership announcements tied to this contract."}